Clinical safety of gadopentetate dimeglumine

Radiology

Volumn 196, Issue 2, 1995, Pages 439-443

  Nelson, Kevin L ^a   Gifford, Lawrence M ^b   Lauber Huber, Cynthia ^b   Gross, Carol A ^b   Lasser, Thomas A ^a,b  

^a Dept of Drug Safety and Survlnc ^*  (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

Contrast media, effects; Gadolinium; Magnetic resonance (MR), safety

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADOLESCENT; AGED; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFANT; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; RASH; URTICARIA; VERTIGO;

EID: 0029093751     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.196.2.7617858     Document Type: Article

References (18)

1. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 1984; 142:619-624.
2. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16:167-172.
3. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR 1984; 143:215-224.
4. Graif M, Bydder GM, Steiner RE, et al. Contrast-enhanced MR imaging of malignant brain tumors. AJNR 1985; 6:855-862.
5. Felix R, Schorner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985; 156:681-688.
6. Healy MR, Hesselink JR, Press GA, Middleton MS. Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 1987; 165:619-624.
7. Hueftle MG, Modic MT, Ross JS, et al. Lumbar spine: postoperative MR imaging with Gd-DTPA. Radiology 1988; 167:817-824.
8. Elster AD, Moody DM. Early cerebral infarction: gadopentetate dimeglumine enhancement. Radiology 1990; 177:627-632.
9. Hudgins PA, Elster AD, Runge VM, Kashanian FK, Goldstein HA. Efficacy and safety of gadopentetate dimeglumine in the evaluation of patients with a suspected tumor of the extracranial head and neck. JMRI 1993; 3:345-349.
10. Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991; 13:15-20.
11. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991; 22:222-228.
12. Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990; 174:17-23.
13. Russell EJ, Schaible TF, Dillon W, et al. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. AJR 1989; 152:813-823.
14. Ge HL, Hirsch WL, Wolf GL, Rubin RA, Hackett RK. Diagnostic role of gadolinium-DTPA in pediatric neuroradiology: a retrospective review of 655 cases. Neuroradiology 1992; 34:122-125.
15. Kashanian FK, Goldstein HA, Blumetti RF, Holyoak WL, Hugo FP, Dolker M. Rapid bolus injection of gadopentetate dimeglumine: absence of side effects in normal volunteers. AJNR 1990; 11:853-856.
16. Kanal E, Applegate GR, Gillen CP. Review of adverse reactions, including anaphylaxis, in 4,260 intravenous bolus injections (abstr). Radiology 1990; 177(P):159.
17. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. Radiology 1990; 175:621-628.
18. Salonen OLM. Case of anaphylaxis and four cases of allergic reactions following Gd-DTPA administration. J Comput Assist Tomogr 1990; 14:912-913.